Evidence map›Paper›PMID 35671983›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2022

Stealth oxime ether lipid vesicles promote delivery of functional DsiRNA in human lung cancer A549 tumor bearing mouse xenografts.

Anu Puri, Faisal Ibrahim, André O'Reilly Beringhs, Camryn Isemann, Paul Zakrevsky, Abigail Whittenburg, Derek Hargrove, Tapan Kanai, Rebecca S Dillard, Natalia de Val and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Anu PuriRNA Structure and Design Section, RNA Biology Laboratory, NCI-NIH, Frederick, MD, United States of America. Electronic address: puria@mail.nih.gov.
Faisal IbrahimRNA Structure and Design Section, RNA Biology Laboratory, NCI-NIH, Frederick, MD, United States of America; Department of Chemistry, University of Louisville, Louisville, KY, United States of America.
André O'Reilly BeringhsSchool of Pharmacy, University of Connecticut, Storrs, CT, United States of America.
Camryn IsemannRNA Structure and Design Section, RNA Biology Laboratory, NCI-NIH, Frederick, MD, United States of America.
Paul ZakrevskyRNA Structure and Design Section, RNA Biology Laboratory, NCI-NIH, Frederick, MD, United States of America.
Abigail WhittenburgRNA Structure and Design Section, RNA Biology Laboratory, NCI-NIH, Frederick, MD, United States of America.
Derek HargroveSchool of Pharmacy, University of Connecticut, Storrs, CT, United States of America.
Tapan KanaiCentre for Molecular Microscopy, FNLCR, Leidos Biomedical Research, Inc., Frederick, MD, United States of America.
Rebecca S DillardCentre for Molecular Microscopy, FNLCR, Leidos Biomedical Research, Inc., Frederick, MD, United States of America.
Natalia de ValCentre for Molecular Microscopy, FNLCR, Leidos Biomedical Research, Inc., Frederick, MD, United States of America.
Michael H NantzDepartment of Chemistry, University of Louisville, Louisville, KY, United States of America.
Xiuling LuSchool of Pharmacy, University of Connecticut, Storrs, CT, United States of America.
Bruce A ShapiroRNA Structure and Design Section, RNA Biology Laboratory, NCI-NIH, Frederick, MD, United States of America. Electronic address: shapirbr@mail.nih.gov.
Leidos Biomedical Research Inc. (United States)University of Connecticut · USUniversity of Louisville · US

Funding

CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

We previously reported that hydroxylated oxime ether lipids (OELs) efficiently deliver functional Dicer substrate siRNAs (DsiRNAs) in cells. Here, we explored in vivo utility of these OELs, using OEL4 as a prototype and report that surface modification of the OEL4 formulations was essential for their in vivo applications. These surface-modified OEL4 formulations were developed by inclusion of various PEGylated lipids. The vesicle stability and gene knock-down were dependent on the PEG chain length. OEL4 containing DSPE-PEG350 and DSPE-PEG1000 (surprisingly not DSPE2000) promoted gene silencing in cells. In vivo studies demonstrated that OEL4 vesicles formulated using 3 mol% DSPE-PEG350 accumulate in human lung cancer (A549-luc2) xenografts in mice and exhibit a significant increase in tumor to liver ratios. These vesicles also showed a statistically significant reduction of luciferase signal in tumors compared to untreated mice. Taken together, the scalable OEL4:DSPE-PEG350 formulation serves as a novel candidate for delivery of RNAi therapeutics.

Indexed as

EtherLung NeoplasmsAnimalsEthersHeterograftsHumansLipidsMiceOximesPolyethylene GlycolsRNA, Small InterferingEtherEthersLipidsOximesPolyethylene GlycolsRNA, Small InterferingCationic lipids-RNA complexesGene silencingLung cancerOxime ether lipidsPEGylated vesiclesRNA interference (RNAi)RNA therapeuticsStealth nanomedicine

Identifiers

PMID35671983
PMCPMC9427711
OpenAlexW4281653737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.